Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone?
- PMID: 12359844
- DOI: 10.1093/jnci/94.19.1422
Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone?
Comment on
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458. J Natl Cancer Inst. 2002. PMID: 12359855 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
